Literature DB >> 22933871

Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC.

Douglas C Wolf1, Bincy P Abraham, Anita Afzali, Paul D Allegretti, Ronen Arai.   

Abstract

Diagnosis of inflammatory bowel disease (IBD) is complicated and is based on a combination of patient history and physical examination in association with laboratory, endoscopic, histologic, and radiographic investigations. Determination of the correct diagnosis is important for its implications in selecting treatment and in the timing and type of surgery that may be required. Information from testing incorporating serologic, genetic, and inflammatory markers can help to clarify the clinical picture. Measurement of biomarkers not only helps to differentiate a diagnosis of IBD versus non-IBD, it can also help to distinguish between ulcerative colitis and Crohn's disease in difficult cases. In this monograph, 5 cases illustrate how specialized testing can provide important information that can aid in diagnosis.

Entities:  

Year:  2012        PMID: 22933871      PMCID: PMC3424421     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  15 in total

1.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.

Authors:  M Peeters; S Joossens; S Vermeire; R Vlietinck; X Bossuyt; P Rutgeerts
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

2.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.

Authors:  F M Ruemmele; S R Targan; G Levy; M Dubinsky; J Braun; E G Seidman
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

3.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  J F Quinton; B Sendid; D Reumaux; P Duthilleul; A Cortot; B Grandbastien; G Charrier; S R Targan; J F Colombel; D Poulain
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

4.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

5.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Authors:  Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

6.  VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.

Authors:  S Kanazawa; T Tsunoda; E Onuma; T Majima; M Kagiyama; K Kikuchi
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

7.  Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

Authors:  Michael Economou; Thomas A Trikalinos; Konstantinos T Loizou; Epameinondas V Tsianos; John P A Ioannidis
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  Adhesion molecules in inflammatory bowel disease.

Authors:  S C Jones; R E Banks; A Haidar; A J Gearing; I K Hemingway; S H Ibbotson; M F Dixon; A T Axon
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

9.  C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.

Authors:  M Henriksen; J Jahnsen; I Lygren; N Stray; J Sauar; M H Vatn; B Moum
Journal:  Gut       Date:  2008-06-19       Impact factor: 23.059

10.  Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease.

Authors:  Sheila A Fisher; Mark Tremelling; Carl A Anderson; Rhian Gwilliam; Suzannah Bumpstead; Natalie J Prescott; Elaine R Nimmo; Dunecan Massey; Carlo Berzuini; Christopher Johnson; Jeffrey C Barrett; Fraser R Cummings; Hazel Drummond; Charlie W Lees; Clive M Onnie; Catherine E Hanson; Katarzyna Blaszczyk; Mike Inouye; Philip Ewels; Radhi Ravindrarajah; Andrew Keniry; Sarah Hunt; Martyn Carter; Nick Watkins; Willem Ouwehand; Cathryn M Lewis; Lon Cardon; Alan Lobo; Alastair Forbes; Jeremy Sanderson; Derek P Jewell; John C Mansfield; Panos Deloukas; Christopher G Mathew; Miles Parkes; Jack Satsangi
Journal:  Nat Genet       Date:  2008-04-27       Impact factor: 38.330

View more
  5 in total

1.  Decreased levels of serum omentin-1 in patients with inflammatory bowel disease.

Authors:  Jian Yin; Peng Hou; Zhiqiang Wu; Yanxiao Nie
Journal:  Med Sci Monit       Date:  2015-01-10

2.  Protective Effect of Pogostone on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis via Inhibition of T Helper Cell.

Authors:  Jiyan Su; Cailan Li; Xiuting Yu; Guanghua Yang; Jianhua Deng; Ziren Su; Huifang Zeng; Jiannan Chen; Xiaojun Zhang; Xiaoping Lai
Journal:  Front Pharmacol       Date:  2017-11-17       Impact factor: 5.810

3.  Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles.

Authors:  Zoltan H Nemeth; Dorian A Bogdanovski; Patricia Barratt-Stopper; Samantha R Paglinco; Luca Antonioli; Rolando H Rolandelli
Journal:  Cureus       Date:  2017-04-19

4.  Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis.

Authors:  Ying Zhuge; Qiu-Ping Huang; Qing Li; Jun-Shan Wang
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-12-01

5.  JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.

Authors:  Rui Zhou; Ying Chang; Jing Liu; Min Chen; Hongling Wang; Meifang Huang; Shi Liu; Xiaobing Wang; Qiu Zhao
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.